HC Wainwright & Co. Reiterates Buy on Alpine Immune Sciences, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a price target of $17.
September 13, 2023 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences has received a reiterated 'Buy' rating and a maintained price target of $17 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Alpine Immune Sciences. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100